+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast to 2030- Product Image
Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast to 2030- Product Image
Sale

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968717
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmaceutical Contract Manufacturing Market grew from USD 123.64 billion in 2024 to USD 134.44 billion in 2025. It is expected to continue growing at a CAGR of 8.49%, reaching USD 201.64 billion by 2030.

Navigating the New Era in Pharmaceutical Contract Manufacturing

The global pharmaceutical contract manufacturing sector stands at a pivotal juncture, shaped by technological breakthroughs, regulatory shifts, and evolving supply chain imperatives. This report opens with an overview of the forces driving demand for outsourced services, from the rising complexity of biologics development to the cost pressures influencing small molecule production. It outlines the interplay between sponsors, contract organizations, and regulatory bodies, highlighting the seamless collaboration required to expedite time-to-market while ensuring quality and compliance.

By setting the stage with current market drivers, stakeholder priorities, and macroeconomic factors, the introduction clarifies why contract manufacturing is no longer a cost-saving afterthought but rather a strategic cornerstone for innovators and generics alike. Readers will gain an immediate understanding of how capacity constraints, specialized service offerings, and risk management considerations shape investment decisions and partnership models. This foundation ensures that subsequent sections can dive deeply into the transformative trends and nuanced segmentation that define the sector’s next phase of growth.

Emerging Dynamics Reshaping Contract Manufacturing

The landscape of contract manufacturing has undergone dramatic transformation fueled by digitization, novel modalities, and agile production paradigms. Rapid advances in continuous processing and single-use technologies have reduced batch times and lowered contamination risks, enabling contract facilities to pivot quickly between complex biologics and high-purity small molecules. Meanwhile, the integration of artificial intelligence and advanced analytics into process development and quality control has accelerated method optimization and predictive maintenance, reshaping service expectations across the board.

Moreover, sustainability imperatives are driving greener chemistry adoption and energy-efficient facility designs, compelling organizations to reevaluate their sourcing, waste management, and carbon footprint strategies. This shift toward eco-conscious manufacturing coexists with heightened regulatory scrutiny around supply chain transparency, prompting contract developers to invest in serialization, blockchain-enabled traceability, and digital document management. As a result, the sector is witnessing a strategic convergence of innovation, compliance, and environmental stewardship that redefines competitive advantage.

How 2025 U.S. Tariff Changes Are Altering Supply Chains

In 2025, the imposition of additional U.S. tariffs on select pharmaceutical ingredients and finished products introduced new complexities into global supply chains. Companies sourcing critical raw materials from Asia have had to reassess import strategies to mitigate cost increases that impact margin projections. Some contract organizations responded by reengineering supply networks to leverage alternative suppliers in tariff-exempt jurisdictions, while others accelerated nearshoring initiatives to maintain price stability and ensure uninterrupted production.

These tariff measures have also incentivized strategic inventory management, pushing firms to adopt just-in-case models alongside just-in-time approaches to buffer against potential rate hikes or policy fluctuations. Consequently, contract manufacturers are negotiating longer-term supply agreements and exploring vendor-financing arrangements to safeguard against working-capital strain. The ultimate outcome is a recalibrated value chain that balances cost containment with the agility to adapt to evolving trade regulations.

Unveiling Critical Market Segmentation Patterns

A nuanced understanding of service divisions reveals pivotal growth corridors. Analytical services, which encompass bioanalytical assays, method development, and stability testing, have become indispensable for ensuring biologics viability and small molecule integrity. Parallel to this, formulation and process development under the development services umbrella are critical for translating lab-scale innovations into robust, scalable protocols. In filling operations, the rising demand for syringe, vial, and unit dose filling underscores the expanding market for self-administered injectables and precision dosing.

Broader manufacturing capabilities span liquid orals, solid dosage forms, sterile injectables, and topical formulations, each addressing distinct therapeutic and delivery challenges. Proven expertise in primary and secondary packaging supports secure distribution and regulatory compliance. The molecule landscape is divided between large, complex biologics and traditional small molecule entities, with dosage forms ranging from oral solutions and suspensions to capsules, tablets, creams, ointments, gels, and advanced injectables. Customer profiles include biosimilar developers, generic producers, and innovator companies seeking dedicated or non-dedicated contract arrangements. Whether navigating clinical phases I through III or scaling to commercial production, firms must choose between batch or continuous processes to optimize yield, quality, and cost efficiency.

Regional Developments Driving Market Opportunities

Regional dynamics illustrate diverse opportunity sets and risk profiles. In the Americas, particularly in North America, the presence of established life sciences clusters and favorable regulatory incentives accelerates biologics outsourcing and high-volume manufacturing. This region’s robust IP protection and advanced infrastructure support collaborative partnerships between sponsors and contract manufacturers, driving innovation in next-generation therapies.

Across Europe, the Middle East, and Africa, strong generic markets coexist with cutting-edge R&D hubs, creating a dual focus on cost-effective production and technological excellence. The EMEA region’s stringent regulatory environment fosters high standards in quality systems, while emerging centers in the Middle East are investing heavily in biotech capabilities. Meanwhile in Asia-Pacific, rapid capacity expansion and competitive cost structures have made this region a global powerhouse for both biologics development and small molecule manufacturing. Government incentives and public-private collaborations are fueling facility modernization and workforce upskilling, positioning Asia-Pacific as a critical player in the worldwide supply matrix.

Competitive Landscape and Leading Contract Manufacturers

The competitive arena features both global contract organizations and niche specialists defining the terms of collaboration. Leading players have expanded their footprints through strategic acquisitions, enabling them to offer end-to-end solutions from discovery through commercial production. Others differentiate by investing in proprietary platforms for high-value modalities such as cell and gene therapies, carving out premium service tiers that command higher margins.

A number of mid-sized firms are capitalizing on their agility, forging tailored partnerships with emerging biotech companies that require flexible production slots and customized development plans. These providers leverage targeted investments in automation and digital control systems to deliver rapid turnaround times without compromising regulatory adherence. Together, these diverse business models underscore the importance of aligning capabilities with sponsor priorities, whether that means high-volume generics throughput or specialized biologics process development.

Strategic Imperatives for Contract Manufacturing Executives

Industry executives should prioritize integrated digital ecosystems that connect process development, supply chain tracking, and quality management under a unified data infrastructure. By doing so, they can eliminate siloes, reduce cycle times, and proactively identify bottlenecks. It is imperative to cultivate strategic supplier relationships with multiple raw material vendors across different regions to mitigate tariff exposure and logistical disruptions.

Furthermore, investing in scalable single-use systems and continuous processing platforms will enable rapid pivoting between product lines, delivering both time and cost efficiencies. Organizations should also adopt sustainability frameworks that align with global environmental targets, reinforcing corporate responsibility while appealing to increasingly eco-conscious clients. Finally, creating cross-functional teams that bring together R&D, operations, regulatory affairs, and commercial strategy will ensure a holistic approach to project execution and market launch readiness.

Methodical Approach to Comprehensive Market Analysis

This analysis leverages a multi-tiered methodology combining primary interviews with C-suite executives, operational leaders, and regulatory experts, alongside secondary data from industry publications, trade associations, and regulatory filings. Qualitative insights from site visits and technology demonstrations were triangulated with quantitative performance metrics to assess service capabilities, capacity constraints, and technological maturity across leading contract organizations.

Market segmentation was validated through a bottom-up approach, aligning service types, dosage forms, customer categories, therapeutic areas, contract models, and process modalities with historical volume data and regulatory approval trends. Regional market scopes were defined by economic indicators, policy frameworks, and capital expenditure patterns. Competitive benchmarking employed both financial and operational KPIs to map the evolving landscape and identify potential disrupters.

Synthesizing Insights for Future-Ready Strategies

The contract manufacturing sector is entering a dynamic phase characterized by technological innovation, regulatory complexity, and geopolitical influences. From the granular demands of analytical testing to the broad imperatives of sustainable production, each facet of this ecosystem requires agile strategies and robust infrastructure. Leaders who embrace digital transformation, diversify supply networks, and invest in flexible manufacturing platforms will be best positioned to capture growth opportunities and navigate evolving trade policies.

As the market continues to segment by service type, molecule class, dosage form, and customer needs, the ability to synthesize cross-functional insights will define success. Organizations that integrate data-driven decision-making with collaborative partnerships across the value chain will achieve faster market entry, enhanced operational resilience, and superior cost management. In this context, the findings presented here serve as a blueprint for designing resilient, future-ready contract manufacturing strategies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Analytical Services
      • Bioanalytical Services
      • Method Development
      • Stability Studies
    • Development Services
      • Formulation Development
      • Process Development
    • Filling Services
      • Syringe Filling
      • Unit Dose Filling
      • Vial Filling
    • Manufacturing Services
      • Liquid Orals
      • Solid Oral Dosage
      • Sterile Injectables
      • Topical Formulations
    • Packaging & Labeling
      • Primary Packaging
      • Secondary Packaging
  • Molecule Type
    • Biologics
    • Small Molecule
  • Dosage Form
    • Liquid Dosage
      • Oral Solutions
      • Suspensions
    • Solid Dosage
      • Capsules
      • Tablets
    • Sterile Injectables
    • Topical Dosage
      • Creams & Ointments
      • Gels
  • Customer Type
    • Biosimilar Manufacturers
    • Generic Manufacturers
    • Innovator Manufacturers
  • Therapeutic Area
    • Cardiovascular
    • CNS
    • Infectious Diseases
    • Oncology
  • Contract Type
    • Dedicated
    • Non Dedicated
  • Production Scale
    • Clinical Trial
      • Phase I
      • Phase II
      • Phase III
    • Commercial
  • Process Type
    • Batch
    • Continuous
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Lonza Group AG
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Samsung Biologics Co., Ltd.
  • Wuxi AppTec Co., Ltd.
  • Fujifilm Diosynth Biotechnologies US, LLC
  • Recipharm AB
  • Siegfried Holding AG
  • Cambrex Corporation
  • PCI Pharma Services, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmaceutical Contract Manufacturing Market, by Service Type
8.1. Introduction
8.2. Analytical Services
8.2.1. Bioanalytical Services
8.2.2. Method Development
8.2.3. Stability Studies
8.3. Development Services
8.3.1. Formulation Development
8.3.2. Process Development
8.4. Filling Services
8.4.1. Syringe Filling
8.4.2. Unit Dose Filling
8.4.3. Vial Filling
8.5. Manufacturing Services
8.5.1. Liquid Orals
8.5.2. Solid Oral Dosage
8.5.3. Sterile Injectables
8.5.4. Topical Formulations
8.6. Packaging & Labeling
8.6.1. Primary Packaging
8.6.2. Secondary Packaging
9. Pharmaceutical Contract Manufacturing Market, by Molecule Type
9.1. Introduction
9.2. Biologics
9.3. Small Molecule
10. Pharmaceutical Contract Manufacturing Market, by Dosage Form
10.1. Introduction
10.2. Liquid Dosage
10.2.1. Oral Solutions
10.2.2. Suspensions
10.3. Solid Dosage
10.3.1. Capsules
10.3.2. Tablets
10.4. Sterile Injectables
10.5. Topical Dosage
10.5.1. Creams & Ointments
10.5.2. Gels
11. Pharmaceutical Contract Manufacturing Market, by Customer Type
11.1. Introduction
11.2. Biosimilar Manufacturers
11.3. Generic Manufacturers
11.4. Innovator Manufacturers
12. Pharmaceutical Contract Manufacturing Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular
12.3. CNS
12.4. Infectious Diseases
12.5. Oncology
13. Pharmaceutical Contract Manufacturing Market, by Contract Type
13.1. Introduction
13.2. Dedicated
13.3. Non Dedicated
14. Pharmaceutical Contract Manufacturing Market, by Production Scale
14.1. Introduction
14.2. Clinical Trial
14.2.1. Phase I
14.2.2. Phase II
14.2.3. Phase III
14.3. Commercial
15. Pharmaceutical Contract Manufacturing Market, by Process Type
15.1. Introduction
15.2. Batch
15.3. Continuous
16. Americas Pharmaceutical Contract Manufacturing Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Pharmaceutical Contract Manufacturing Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Pharmaceutical Contract Manufacturing Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Lonza Group AG
19.3.2. Catalent, Inc.
19.3.3. Thermo Fisher Scientific Inc.
19.3.4. Samsung Biologics Co., Ltd.
19.3.5. Wuxi AppTec Co., Ltd.
19.3.6. Fujifilm Diosynth Biotechnologies US, LLC
19.3.7. Recipharm AB
19.3.8. Siegfried Holding AG
19.3.9. Cambrex Corporation
19.3.10. PCI Pharma Services, Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 107. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 108. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 109. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 110. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 111. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 112. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 114. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 115. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 116. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 117. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 118. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 119. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 120. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 121. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 122. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 124. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 125. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 126. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 127. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 129. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 131. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 134. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 136. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 139. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 209. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 210. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 211. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 212. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 213. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 214. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 215. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 217. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 218. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 219. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 220. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 221. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 222. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 223. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 224. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 225. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 226. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 227. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 228. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 229. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 230. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 231. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 232. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 234. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 236. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 237. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 238. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 239. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 240. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 241. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 242. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 260. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 261. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 262. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 263. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 264. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 265. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2030 (USD MILLION)
TABLE 266. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 267. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2030 (USD MILLION)
TABLE 269. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2030 (USD MILLION)
TABLE 270. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2030 (USD MILLION)
TABLE 271. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2030 (USD MILLION)
TABLE 272. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 273. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2030 (USD MILLION)
TABLE 274. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 275. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
TABLE 276. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2030 (USD MILLION)
TABLE 277. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 278. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 279. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 280. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2030 (USD MILLION)
TABLE 281. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 282

Companies Mentioned

The companies profiled in this Pharmaceutical Contract Manufacturing market report include:
  • Lonza Group AG
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Samsung Biologics Co., Ltd.
  • Wuxi AppTec Co., Ltd.
  • Fujifilm Diosynth Biotechnologies US, LLC
  • Recipharm AB
  • Siegfried Holding AG
  • Cambrex Corporation
  • PCI Pharma Services, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 134.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 201.64 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pharmaceutical Contract Development & Manufacturing Market by Service Type, Technology, Development Stage, End Use, Customer Type - Global Forecast to 2030 - Product Image

Pharmaceutical Contract Development & Manufacturing Market by Service Type, Technology, Development Stage, End Use, Customer Type - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Pharmaceutical Contract Manufacturing & Research Services Market by Service Type, End-User - Global Forecast to 2030 - Product Image

Pharmaceutical Contract Manufacturing & Research Services Market by Service Type, End-User - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Semi-solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Topical, Transdermal, Oral), By Product (Creams, Gels), By End Use, By Company Size, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Semi-solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Topical, Transdermal, Oral), By Product (Creams, Gels), By End Use, By Company Size, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Innovative, Generic), Dosage Form (Injectable, Creams), Application, Synthesis, Region, and Segment Forecasts, 2025-2030 - Product Image

High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report by Product (Innovative, Generic), Dosage Form (Injectable, Creams), Application, Synthesis, Region, and Segment Forecasts, 2025-2030

  • Report
  • 130 Pages
  • Global
From
Semi-Solid Dosage Contract Manufacturing - Global Strategic Business Report - Product Image

Semi-Solid Dosage Contract Manufacturing - Global Strategic Business Report

  • Report
  • 71 Pages
  • Global
From

About the Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing (PCM) is a type of pharmaceutical manufacturing in which a company outsources the production of a drug or medical device to a third-party manufacturer. This type of manufacturing is often used when a company does not have the resources or expertise to produce a product in-house. PCM can also be used to reduce costs, increase production capacity, and improve product quality. PCM services can include formulation development, process optimization, analytical testing, packaging, and labeling. The contract manufacturer is responsible for ensuring that the product meets all regulatory requirements and is of the highest quality. Some of the major players in the PCM market include Patheon, Catalent, Recipharm, Aenova, and Vetter. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.